(HealthDay News) — For healthy adults challenged with respiratory syncytial virus (RSV), an oral RSV-entry inhibitor, GS-5806, is associated with reduced viral load, according to a study published in the August 21 issue of the New England Journal of Medicine.

John P. DeVincenzo, MD, from the University of Tennessee School of Medicine in Memphis, and colleagues conducted a study of GS-5806 in healthy adults who received a clinical challenge strain of RSV intranasally. Participants were randomly assigned to receive GS-5806 or placebo in one of seven cohorts at the time of a positive test for RSV infection or five days after inoculation. Cohorts 1–4 received a first dose of 50mg of GS-5806 and 25mg daily for the next four days. For cohorts 5, 6, and 7, the dose was selected after an interim analysis of data from cohorts 1–4.

The researchers found that active treatment correlated with a lower viral load, lower total mucus weight, and a lower area under the curve for the change from baseline in symptom scores among the 54 participants in cohorts 1–4 who were infected with RSV. Similar results were seen in cohorts 5, 6, and 7. Participants receiving GS-5806 had adverse events more frequently, including low neutrophil counts and increased levels of alanine aminotransferase.

“Treatment with GS-5806 reduced the viral load and the severity of clinical disease in a challenge study of healthy adults,” the authors write.

The study was funded by Gilead Sciences, the manufacturer of GS-5806.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)